Medical treatment of vertebral osteoporosis

European Spine Journal

Volumn 12, Issue SUPPL. 2, 2003, Pages

  Lippuner, K ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Medical treatment; Number needed to treat; Osteoporosis; Relative risk reduction; Review; Vertebral fractures

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ERGOCALCIFEROL; ETIDRONIC ACID; FLUORIDE; IPRIFLAVONE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PARATHYROID HORMONE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM; TILUDRONIC ACID; VITAMIN D;

CALCULATION; CAUCASIAN; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DECISION MAKING; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INTERVERTEBRAL DISK DEGENERATION; LONG TERM CARE; MAJOR CLINICAL STUDY; META ANALYSIS; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL DISABILITY; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMIC DISEASE; TISSUE DISTRIBUTION; VERTEBRA FRACTURE;

AGED; CALCITONIN; DIPHOSPHONATES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPINAL FRACTURES;

EID: 0242488878     PISSN: 09406719     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00586-003-0608-x     Document Type: Review

References (95)

1. Adachi JD, Bensen WG, Brown J, et al (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387
2. Adachi JD, Saag KG, Delmas PD, et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. Arthritis Rheum 44:202-211
3. Adinoff AD, Hollister JR (1983) Steroid-induced fractures and bone loss in patients with asthma. New Engl J Med 309:265-268
4. Adler RA, Rosen CJ (1994) Glucocorticoids and osteoporosis. Endocrinol Metab Clin North Am 23:641-654
5. Alexandersen P, Riis BJ, Christiansen C (1999) Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocrinol Metab 84:3013-3020
6. Alexandersen P, Toussaint A, Christiansen C, Devogelaer P, et al (2001) Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 285:1482-1488
7. Aloia JF, Vaswani A, Yen JK, Ellis K, et al (1988) Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 84:401-408
8. Amin S, Lavalley M, Simms RW, Felson DT (2002) The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 17:1512-1526
9. Black DM, Palermo L, Nevitt MC, et al (1995) Comparison of methods for defining prevalent vertebral deformities: the study of osteoporotic fractures. J Bone Miner Res 10:890-902
10. Black DM, Cummings SR, Karpf DB, Cauley JA, et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
11. Black DM, Thompson D, Bauer DC, Ensrud K, et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118-4124
12. Blau LA, Hoehns JD (2003) Analgesic efficacy of calcitonin for vertebral fracture pain. Ann Pharmacother 37:564-570
13. Bombardier C, Laine L, Reicin A, et al - VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520-1528
14. Bone HG (2001) Development and evaluation of new drugs for osteoporosis. Osteoporosis (Second Edition) 2: 533-538
15. Bone HG, Downs RW, Tucci JR Harris ST, et al (1997) Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 82:265-274
16. Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn P, et al (2002) Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 17:1057-1064
17. Burger H, Van Daele PL, Algra D, et al (1994) Vertebral deformities as predictors of non-vertebral fractures. BMJ 309:991-992
18. Canalis E (2003) Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 15:454-457
19. Cauley JA, Black DM, Barrett-Connor E, Harris F, et al (2001) Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med 110:442-450
20. Chesnut CH, Silverman S, Andriano K, Genant H, et al (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence Of Osteoporotic Fractures study. Am J Med 109:267-276
21. Chevalley T, Rizzoli R, Nydegger V, Slosman D, et al (1994) Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos Int 4:245-252
22. Clemmesen B, Ravn P, Zegels B, Taquet AN, et al (1997) A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 7:488-495
23. Cohen S, Levy RM, Keller M, Boling E, et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309-2318
24. Consensus Development Conference (1993) Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646-650
25. Cranney A, Welch V, Adachi JD, Homik J, et al (2000) Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:1983
26. Cummings SR, Nevitt MC, Browning WR, et al (1995) Risk factors for hip fracture in white women. N Engl J Med 322:767-773
27. Cummings SR, Black DM, Thompson DE, Applegate WB, et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082
28. Delmas PD, Ensrud KE, Adachi JD, Harper KD, et al (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617
29. Dursun N, Dursun E, Yalcin S (2001) Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract 55:505-509
30. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645
31. Falch JA, Odegaard OR, Finnanger AM, Matheson I (1987) Postmenopausal osteoporosis: no effect of three years treatment with 1, 25- dihydroxycholecalciferol. Acta Med Scand 221: 199-204
32. Fogelman I, Ribot C, Smith R, Ethgen D, et al (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 85:1895-1900
33. Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 113:649-655
34. Gallagher JC, Riggs BL, Recker RR, Goldgar D (1989) The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 191:287-292
35. Greenspan S, Myers E, Maitland L, et al (1994) Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA 271: 128-133
36. Gutteridge DH, Stewart GO, Prince RL, Price RI et al. (2002) A randomized trial of sodium fluoride (60 mg) ± estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures. Osteoporos Int 13:158-170
37. Harris ST, Watts NB, Jackson RD, Genant HK, et al (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-567
38. Harris ST, Watts NB, Genant HK, McKeever CD, et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344-1352
39. Häuselmann HJ, Rizzoli R (2003) A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 14:2-12
40. Heikki Frick M, Elo O, Haapa A, et al (1987) Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. New Engl J Med 317:1237-1245
41. Hizmetli S, Elden H, Kaptanoglu E, Nacitarhan V, et al (1998) The effect of different doses of calcitonin on bone mineral density and fracture risk in postmenopausal osteoporosis. Int J Clin Pract 52:453-455
42. Hulley S, Grady D, Bush T, Furberg C, et al (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605-613
43. Hulley S, Furberg C, Barrett-Connor E, Cauley J, et al (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:58-66
44. Jalava T, Sarna S, Pylkkanen L, et al (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18:1254-1260
45. Kanis JA, Brazier JE, Stevenson M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment 6(29)
46. Kleerekoper M, Peterson EL, Nelson DA, Phillips E, et al (1991) A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1:155-161
47. Lafague-Proust MH, Boudignon B, Thierry T (2003) Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments. Joint Bone Spine 70:109-118
48. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 102:1627-1633
49. Levis S, Quandt SA, Thompson D, Scott J, et al (2002) Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 50:409-415
50. Liberman UA, Weiss SR, Bröll J, Minne HW, et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
51. Lindsay R, Nieves J, Formica C, Henneman E, et al (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555
52. Luengo M, Picado C, Dei Rio L, et al (1991) Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Thorax 46:803-806
53. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, et al (1992) Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:1-9
54. Lyritis GP, Tsakalakos N, Papspati I, Skarantavos G, et al (1997) The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study. Clin Rheumatol 16: 354-360
55. McCloskey E, Selby P, De Takats D, Bernard J, et al (2001) Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone 28:310-315
56. McClung MR, Geusens P, Miller PD, Zippel H, et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340
57. McKeogh DF (2003) Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding. N Engl J Med 348:2464-2466
58. Melton LJ, Kan SH, Frye MA, et al (1989) Epidemiology of vertebral fractures in women. Am J Epidemiol 129: 1000-1011
59. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, et al (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo-controlled trial. J Clin Endocrinol Metab 87:2060-2066
60. Naganathan V, Jones G, Nash P, et al (2000) Vertebral fracture risk with long-term corticosteroid therapy. Arch Intern Med 160:2917-2922
61. Neer RM, Arnaud CD, Zanchetta JR, Prince R, et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
62. Neuner JM, Zimmer, JK, Hamel MB (2003) Diagnosis and treatment of osteoporosis in patients with vertebral compression fractures. J Am Geriatr Soc 51:483-491
63. Nevitt MC, Ettinger B, Black DM (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793-800
64. Orwoll E, Ettinger M, Weiss S, et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610
65. Osteoporosis Methodology Group and Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Rev 23:495-578
66. Ott SM, Chesnut CH (1989) Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 110:267-274
67. Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 305:556-561
68. Pak CY, Sakhaee K, Adams-Huet B, Piziak V, et al (1995) Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 123:401-408
69. Recker RR, Hinders S, Davies KM, Heaney RP, et al (1996) Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 11:1961-1966
70. Recker RR, Davies KM, Dowd RM, Heaney RP (1999) The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized controlled trial. Ann Intern Med 130:897-904
71. Reginster JY, Meurmans L, Zegels B, Rovati LC, et al (1998) The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 129:1-8
72. Reginster JY, Minne HW, Sorensen OH, Hooper M, et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
73. Reginster JY, Christiansen C, Roux C, Fechtenbaum J, et al (2001) Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos Int 12: 169-177
74. Reid DM, Hughes RA, Laan RF, et al (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006-1013
75. Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy, Calcif Tiss Int 69:242-247
76. Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, et al (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809
77. Ringe JD, Kipshoven C, Cöster A, Umbach R (1999) Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate. Osteoporos Int 9:171-178
78. Ringe JD, Faber H, Dorst A (2001) Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 86:5252-5255
79. Ross PD, Davis JW, Epstein RS, et al (1991) Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114: 919-923
80. Ryan PJ, Blake GM, Davie M, Haddaway M, et al (2000) Intermittent oral disodium pamidronate in established osteoporosis: A 2-year double-masked placebo-controlled study of efficacy and safety. Osteoporos Int 11:171-176
81. Saag KG, Emekey R, Schnitzer TJ, et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299
82. Sambrook PN, Kotowicz M, Hash P, et al (2003) Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium and alendronate plus calcium. J Bone Miner Res 18:919-924
83. Silverstein FE, Graham DY, Senior JR, et al (1995) Misoprostol reduces serious gastro-intestinal complications in patients with rheumatoid arthritis receiving non steroidal anti-inflammatory drugs. Ann Int Med 123:241-249
84. Steering Committee of the Physicians' Health Study Group (1989). Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321:129-135
85. Storm T, Thamsborg G, Steiniche T, Genant HK, et al (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271
86. Tilyard MW, Spears GFS, Thomson J, Dovey S, et al (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326: 357-362
87. van Staa TP, Leufkens HG, Cooper C (2001) Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 16:581-588
88. Wallach S, Cohen S, Reid DM, et al (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277-285
89. Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross-sectional study. BMJ 313:344-346
90. Watts NB, Harris ST, Genant HK, Wasnich RD, et al (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79
91. WHO study group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report series. WHO, Geneva
92. Wimalawansa SJ (1998) A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104:219-226
93. Windeler J, Lange S (1995) Events per person year, a dubious concept. BMJ 310:454-456
94. Wong CA, Walsh LJ, Smith CJP, et al (2000) Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet 355:1399-1403
95. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333